Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
58 participants
INTERVENTIONAL
2003-11-30
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Enhancement of Emmetropization in Hyperopic Infants
NCT00574717
Control of Myopia Using Novel Spectacle Lens Designs
NCT03623074
Children's Viewing Behavior
NCT07229365
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
NCT06034327
Efficacy of Chinese Ocular Exercise on Visual Acuity and Ocular Accommodation in Myopic Teenager
NCT01756287
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Spectacles
Spectacles with hyperopic lenses
Spectacles
Hyperopic spectacle lenses
Control
Spectacles with placebo lenses
Control
Plano (no power, control) spectacle lenses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spectacles
Hyperopic spectacle lenses
Control
Plano (no power, control) spectacle lenses
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least +1.00D Hyperopia (farsightedness);
* \< +4.00D Hyperopia;
* \< 1.00D Astigmatism;
* \< 1.00D Anisometropia (difference between the two eyes);
* Willing to be randomized;
* Best corrected visual acuity of 20/25 or better in each eye;
* Willing to wear eyeglasses full-time;
* Willing to return for follow-up visits
Exclusion Criteria
* Eye disease that affects visual function;
* Amblyopia (lazy eye);
* Strabismus (eye turn);
* History of strabismus surgery;
* Chronic use of any of the following medications:
* Antianxiety agents (Librium, Valium)
* Antiarrythmic agents (Cifenline, Cibenzoline)
* Anticholinergics (Motion sickness patch - scopolamine)
* Bladder spasmolytic (Propiverine)
* Chloroquine
* Phenothiazines (Compazine, Mellaril, Thorazine)
* Tricyclic antidepressants (Elavil, Nortriptyline, Tofranil)
6 Years
11 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
American Academy of Optometry
OTHER
Transitions
INDUSTRY
Ohio Lions Eye Research Foundation
OTHER
College of Optometrists in Vision Development
OTHER
SUNY Research Foundation
OTHER
Ohio State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marjean Kulp
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marjean Kulp, OD
Role: PRINCIPAL_INVESTIGATOR
Ohio State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Illinois College of Optometry/Illinois Eye Institute
Chicago, Illinois, United States
SUNY College of Optometry/University Optometric Center
New York, New York, United States
The Ohio State University
Columbus, Ohio, United States
Southern College of Optometry
Memphis, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2001H0401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.